Quick Answer
INTENSITY THERAPEUTICS, INC. reported R&D Expense of $6.79 million for fiscal year 2025.
INTENSITY THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $6.79M | -35.4% |
| 2024 | $10.50M | +119.3% |
| 2023 | $4.79M | -6.7% |
| 2022 | $5.13M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.55M | -27.8% | +0.8% |
| June 30, 2025 | $1.54M | -56.7% | -29.6% |
| March 31, 2025 | $2.19M | -22.2% | +1.8% |
| September 30, 2024 | $2.15M | +59.1% | -39.6% |
| June 30, 2024 | $3.56M | +314.8% | +26.6% |
| March 31, 2024 | $2.81M | +263.7% | +108.2% |
| September 30, 2023 | $1.35M | +16.5% | +57.4% |
| June 30, 2023 | $859.0K | -38.0% | +11.0% |
- INTENSITY THERAPEUTICS, INC. showed a decrease of -35.4% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, INTENSITY THERAPEUTICS, INC.’s r&d expense has grown by 32.2% (from $5.13 million to $6.79 million).
- The most recent figure is from INTENSITY THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: